Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Abcam plc
  6. Summary
    ABC   GB00B6774699

ABCAM PLC

(ABC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/25/2021 10/26/2021 10/27/2021 10/28/2021 10/29/2021 Date
1647(c) 1645(c) 1641(c) 1659(c) 1654(c) Last
114 785 124 568 118 471 122 428 99 891 Volume
+0.12% -0.12% -0.24% +1.10% -0.30% Change
More quotes
Estimated financial data (e)
Sales 2021 318 M 420 M 420 M
Net income 2021 23,8 M 31,5 M 31,5 M
Net cash position 2021 209 M 276 M 276 M
P/E ratio 2021 161x
Yield 2021 -
Sales 2022 378 M 501 M 501 M
Net income 2022 47,7 M 63,1 M 63,1 M
Net cash position 2022 185 M 245 M 245 M
P/E ratio 2022 88,1x
Yield 2022 -
Capitalization 3 819 M 5 050 M 5 053 M
EV / Sales 2021 11,4x
EV / Sales 2022 9,60x
Nbr of Employees 1 650
Free-Float 91,2%
More Financials
Company
Abcam plc is a global life sciences company. The Company is focused on identifying, developing and distributing reagents and tools which are required in the fields of life science research. The Company's product offering includes portfolio of antibodies and related protein research tools that are fundamental to its customers' research and experimental workflow. The Company's product type includes primary antibodies,... 
Sector
Pharmaceuticals
Calendar
03/31Earnings Release
More about the company
Ratings of Abcam plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ABCAM PLC
02:32pABCAM : Regulatory News Service Announcement dated December 02, 2021 - Form 6-K
PU
11/12Regulatory News Service Announcement dated November 10, 2021 - Form 6-K
PU
11/02Nautilus Biotechnology Posts Narrower Q3 Loss
MT
11/02Nautilus Biotechnology, Inc. and Abcam plc Announces Strategic Partnership to Accelerat..
CI
10/27Abcam Completes Acquisition of BioVision - Form 6-K
PU
10/27Abcam Closes Acquisition of BioVision
MT
10/27ABCAM Closes $340 Million BioVision Purchase
MT
10/27Abcam completes $340m strategic acquisition and expands kit capacity and capability
PR
10/27Abcam Expands Kit Capacity and Capability
CI
09/20ABCAM PLC(NASDAQGS : ABCM) dropped from S&P Global BMI Index
CI
09/20ABCAM PLC(AIM : ABC) added to S&P Global BMI Index
CI
09/15WALL STREET STOCK EXCHANGE : Yes, the global economic recovery is slowing
09/15ANALYST RECOMMENDATIONS : Chevron, Centene, Darktrace, Flutter, Malibu Boats...
09/13ADRs End Higher; Adaptimmune Therapeutics Among Companies Actively Trading
DJ
09/13ABCAM : H2 Adjusted EPS, Revenue Rise
MT
More news
News in other languages on ABCAM PLC
11/02Nautilus Biotechnology affiche une perte plus étroite au troisième trimestre
10/27Abcam conclut l'acquisition de BioVision
10/27ABCAM conclut l'achat de BioVision pour 340 millions de dollars
09/15Vamos por buen camino
09/15AVIS D'ANALYSTES DU JOUR : Sodexo, Nestlé, Nexans, Pandora, DSM, Darktrace, Flutter, Crit...
More news
Analyst Recommendations on ABCAM PLC
More recommendations
Chart ABCAM PLC
Duration : Period :
Abcam plc Technical Analysis Chart | ABC | GB00B6774699 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 1 672,00 GBX
Average target price 1 499,98 GBX
Spread / Average Target -10,3%
EPS Revisions
Managers and Directors
Alan Thomas Hirzel Chief Executive Officer & Executive Director
Michael Shaun Baldock Chief Financial Officer & Executive Director
Peter Vance Allen Non-Executive Chairman
Mara G. Aspinall Independent Non-Executive Director
Giles Francis Bertram Kerr Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ABCAM PLC6.71%5 144
CSL LIMITED5.12%98 819
WUXI BIOLOGICS (CAYMAN) INC.0.39%55 833
SAMSUNG BIOLOGICS CO.,LTD.8.96%50 185
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.27%33 568